Back to search

Peptide record

TPDB24749

RGD-Las Antibacterial Anticancer Toxicity Tumor-homing Peptides standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB24749
RGD-Las
Antibacterial Anticancer Toxicity Tumor-homing Peptides
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF TumorHoPe2.0
standard
No
A 16-aa standard natural multi-activity (Antibacterial, Anticancer, Toxicity, and other sources) peptide sequence curated from Peptipedia, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
RGDLLRHVVKILSKYL
Physicochemical Analysis
C88H152N26O21
ANCEQMFPTW
L
1910.34
10.71
5
1
8
+3
2.58
0.131
158.12
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
1490
78.00
2
Residue Composition
number
0
A
2
R
0
N
1
D
0
C
0
E
0
Q
1
G
1
H
1
I
4
L
2
K
0
M
0
F
0
P
1
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 1 L: 4 K: 2 M: 0 F: 0 P: 0 S: 1 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
16
C88H152N26O21
1910.34
10.71
+3
2.58
0.131
Free
L
Linear
Free
Anticancer
Arg-Gly-Asp(RGD) tripeptide ana temporins Arg-Gly-Asp(RGD) tripeptide aNot Available temporins
Evidence Records 14 records
Evidence 1 Activity

Activity

81.465 Inhibition ratio at 50 µg/ml
Anticancer

Target

Colorectal Cancer
SW-1116
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

86.175 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
SMMC-7721
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

78.045 Inhibition ratio at 50 µg/ml
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

73.07 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

73.705 Inhibition ratio at 50 µg/ml
Anticancer

Target

Gastric Cancer
BGC-823
Stomach

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 6 Activity

Activity

52.50 Inhibition ratio at 50 µg/ml
Anticancer

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 7 Activity

Activity

38.13 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
HL7702
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 8 Activity

Activity

32.52 Inhibition ratio at 50 µg/ml
Anticancer

Target

Renal Cancer
HEK-293T
Renal

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 9 Activity

Activity

29.33 Inhibition ratio at 50 µg/ml
Anticancer

Target

Breast Cancer
MEC
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 10 Activity

Activity

38.13±4.19% Inhibition
Toxicity
50 µg/mL
Cytotoxic
38.13±4.19% Inhibition | 50 | µg/mL | target cell: Human hepatocyte cells HL-7702 (L02)

Target

Human hepatocyte cells HL-7702 (L02)

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 11 Activity

Activity

32.52±2.28% Inhibition
Toxicity
50 µg/mL
Cytotoxic
32.52±2.28% Inhibition | 50 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 12 Activity

Activity

29.33±1.39% Inhibition
Toxicity
50 µg/mL
Cytotoxic
29.33±1.39% Inhibition | 50 | µg/mL | target cell: Bovine mammary epithelial cells

Target

Bovine mammary epithelial cells

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 13 Activity

Activity

19.34±2.83% Inhibition
Toxicity
50 µg/mL
Cytotoxic
19.34±2.83% Inhibition | 50 | µg/mL | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 14 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Showed no hemolytic activity against rabbit erythrocytes and human erythrocytes at 250 µg/ml | Cytotoxicity: Showed little effects on the proliferation of the 293T human embryonic kidney cell line, MECs, and human lymphomonocytes at concentrations of less than 50 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
J Pept Sci. 2012 Jul 18(7):476-86.